Edition:
India

Jubilant Life Sciences Ltd (JULS.NS)

JULS.NS on National Stock Exchange of India

704.45INR
18 Apr 2019
Change (% chg)

Rs12.65 (+1.83%)
Prev Close
Rs691.80
Open
Rs694.90
Day's High
Rs708.90
Day's Low
Rs683.20
Volume
393,368
Avg. Vol
499,845
52-wk High
Rs898.85
52-wk Low
Rs586.35

Latest Key Developments (Source: Significant Developments)

Jubilant Life Sciences Says U.S. FDA Issues Warning Letter For Roorkee Facility Of JPL
Friday, 8 Mar 2019 

March 8 (Reuters) - Jubilant Life Sciences Ltd ::SAYS U.S. FDA ISSUED WARNING LETTER FOR THE ROORKEE FACILITY OF JUBILANT PHARMA LIMITED (JPL), ITS UNIT.SAYS EXISTING MANUFACTURING AND SALE OF PRODUCTS FROM ROORKEE FACILITY WILL NOT BE IMPACTED.USFDA MAY WITHHOLD APPROVAL OF ANY NEW APPLICATIONS OR SUPPLEMENTS TILL UNIT ADDRESSES ALL ISSUES RAISED BY AGENCY.  Full Article

Jubilant Life Sciences Issues Commercial Papers Worth 750 Mln Rupees
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Jubilant Life Sciences Ltd ::ISSUED COMMERCIAL PAPERS WORTH 750 MILLION RUPEES.  Full Article

Jubilant Life Sciences Gets ANDA Approval For Niacin Extended-Release Tablets USP
Tuesday, 15 May 2018 

May 15 (Reuters) - Jubilant Life Sciences Ltd ::SAYS JUBILANT RECEIVES ANDA APPROVAL FOR NIACIN EXTENDED-RELEASE TABLETS USP.  Full Article

Jubilant Life Sciences Says Home Dept Stays Order Cancelling Licenses For Co's Distillery Operations At Nira
Wednesday, 7 Mar 2018 

March 7 (Reuters) - Jubilant Life Sciences Ltd ::HOME DEPARTMENT, MAHARASHTRA GOVERNMENT STAYED ORDER ON CANCELLING OF DS-1 LICENSE, FORM-I LICENSE FOR CO'S DISTILLERY OPERATIONS AT NIRA.  Full Article

Jubilant Life Sciences Says Unit Got ANDA Approval For Amantadine Hydrochloride Tablets​
Friday, 9 Feb 2018 

Feb 9 (Reuters) - Jubilant Life Sciences Ltd ::UNIT, JUBILANT PHARMA GETS ANDA FINAL APPROVAL FOR AMANTADINE HYDROCHLORIDE TABLETS, GENERIC VERSION OF SYMMETREL OF ENDO​.  Full Article

Jubilant Life Sciences Unit Gets sNDA Approval For New Indications From USFDA For Draximage DTPA
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - Jubilant Life Sciences Ltd ::SAYS UNIT GETS SNDA APPROVAL FOR NEW INDICATIONS FROM USFDA FOR DRAXIMAGE® DTPA.  Full Article

Jubilant Life Sciences Says Co Not Got Formal Environmental Nod For Gujarat Pesticide Project
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Jubilant Life Sciences Ltd ::CLARIFIES ON NEWS ITEM ON CO'S PESTICIDE PROJECT IN GUJARAT GETTING GREEN PANEL NOD.SAYS CO HAS NOT GOT ANY FORMAL ENVIRONMENTAL NOD FOR GUJARAT PESTICIDE PROJECT.  Full Article

Jubilant Life Sciences says unit gets USFDA approval for Drax Exametazime
Monday, 21 Aug 2017 

Aug 21 (Reuters) - Jubilant Life Sciences Ltd ::Says Jubilant receives NDA approval for Drax Exametazime.Jubilant Pharma , through Jubilant Draximage Inc gets USFDA approval for Drax Exametazime.Approved drug is indicated for leukocyte (white blood cell) labeled scintigraphy.  Full Article

India's Jubilant Life Sciences June-qtr consol profit down about 12 pct
Tuesday, 18 Jul 2017 

July 18 (Reuters) - Jubilant Life Sciences Ltd ::June quarter consol net profit 1.44 billion rupees versus profit of 1.64 billion rupees last year.June quarter consol total income 16.03 billion rupees versus 14.58 billion rupees last year.  Full Article

Jubilant Life Sciences gets ANDA nod for generic drug to treat depression
Thursday, 6 Jul 2017 

July 6 (Reuters) - Jubilant Life Sciences Ltd ::Says Jubilant receives ANDA approval for bupropion hydrochloride extended-release tablets.Says drug intended for treatment of major depressive disorder and prevention of seasonal affective disorder.  Full Article